Skip to content

DERMATA THERAPEUTICS, INC.: 10-Q filed 2025-11-14

What DERMATA THERAPEUTICS, INC. reported in its quarterly report filed 2025-11-14 (fiscal Q3 2025): 24 published measures, 81 facts as tagged in accession 0001493152-25-023474.

This filing

Form
10-Q (quarterly report)
Filed
2025-11-14
Fiscal period
fiscal Q3 2025
Accession
0001493152-25-023474 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All DERMATA THERAPEUTICS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2025-09-305,071,410USD
At 2024-12-313,533,888USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2025-09-301,111,308USD
At 2024-12-311,972,794USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2025-09-303,960,102USD
At 2025-06-305,614,251USD
At 2025-03-317,301,222USD
At 2024-12-311,561,094USD
At 2024-09-304,741,228USD
At 2024-06-303,318,127USD
At 2024-03-313,807,990USD
At 2023-12-316,355,018USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2025-09-304,664,127USD
At 2024-12-313,161,570USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-1,691,989USD92
2025-01-01 to 2025-09-30-5,696,669USD273
2025-04-01 to 2025-06-30-1,701,093USD91
2025-01-01 to 2025-03-31-2,303,587USD90
2024-07-01 to 2024-09-30-3,173,156USD92
2024-01-01 to 2024-09-30-9,136,523USD274
2024-04-01 to 2024-06-30-2,829,106USD91
2024-01-01 to 2024-03-31-3,134,262USD91

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2025-01-01 to 2025-09-30-6,428,362USD273
2024-01-01 to 2024-12-31-11,100,000USD366
2024-01-01 to 2024-09-30-8,249,334USD274

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2025-01-01 to 2025-09-307,930,919USD273
2024-01-01 to 2024-09-306,954,951USD274

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2025-09-30-71,372,008USD
At 2024-12-31-65,675,339USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2025-07-01 to 2025-09-301,026,457shares92
2025-01-01 to 2025-09-30858,015shares273
2024-07-01 to 2024-09-30155,465shares92
2024-01-01 to 2024-09-3089,414shares274

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2025-07-01 to 2025-09-301,026,457shares92
2025-01-01 to 2025-09-30858,015shares273
2024-07-01 to 2024-09-30155,465shares92
2024-01-01 to 2024-09-3089,414shares274

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-1.65USD/shares92
2025-01-01 to 2025-09-30-6.64USD/shares273
2024-07-01 to 2024-09-30-20.41USD/shares92
2024-01-01 to 2024-09-30-102.18USD/shares274

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-1.65USD/shares92
2025-01-01 to 2025-09-30-6.64USD/shares273
2024-07-01 to 2024-09-30-20.41USD/shares92
2024-01-01 to 2024-09-30-102.18USD/shares274

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2025-07-01 to 2025-09-3037,840USD92
2025-01-01 to 2025-09-30114,263USD273
2024-07-01 to 2024-09-3020,992USD92
2024-01-01 to 2024-09-30627,834USD274

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-1,760,671USD92
2025-01-01 to 2025-09-30-5,873,205USD273
2024-07-01 to 2024-09-30-3,225,653USD92
2024-01-01 to 2024-09-30-9,312,954USD274

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2025-09-30453,427USD
At 2024-12-31808,011USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2025-07-01 to 2025-09-301,760,671USD92
2025-01-01 to 2025-09-305,873,205USD273
2024-07-01 to 2024-09-303,225,653USD92
2024-01-01 to 2024-09-309,312,954USD274

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

PeriodValueUnitDays
2025-07-01 to 2025-09-301,256,284USD92
2025-01-01 to 2025-09-303,469,842USD273
2024-07-01 to 2024-09-30824,294USD92
2024-01-01 to 2024-09-303,301,753USD274

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2025-07-01 to 2025-09-30504,387USD92
2025-01-01 to 2025-09-302,403,363USD273
2024-07-01 to 2024-09-302,401,359USD92
2024-01-01 to 2024-09-306,011,201USD274

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2025-09-30844,457shares
At 2024-12-31251,725shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2025-09-304,664,127USD
At 2024-12-313,161,570USD
At 2024-09-306,143,752USD
At 2023-12-317,438,135USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2025-09-3075,332,026USD
At 2024-12-3167,236,408USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2025-09-30407,283USD
At 2024-12-31372,318USD

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2025-01-01 to 2025-09-307,980,804USD273
2024-01-01 to 2024-09-306,955,611USD274

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2025-01-01 to 2025-09-30-304,089USD273
2024-01-01 to 2024-09-30-10,324USD274

Inspect the source

Entity
DERMATA THERAPEUTICS, INC. / CIK 0001853816
Captured
2026-09-21T17:32:45.864Z
SEC response SHA-256
ee7c8299dd660190b4881b2244d4f237e13e69a8d8cbc08e2f3ebeba101aecb3

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001853816.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))